Publication search
with Unfit patients as keyword
Pepe, Sara Scalzulli, Emilia Colafigli, Gioia Di Prima, Alessio Diverio, Daniela Mancini, Marco Latagliata, Roberto Martelli, Maurizio Foà, Robin Breccia, Massimo
...
Published in
Annals of hematology
Predictive factors of response to hypomethylating agents (HMA) in elderly acute myeloid leukemia (AML) patients remain unclear in the real-life setting and no direct comparison between azacitidine (AZA) and decitabine (DEC) has been carried out. We retrospectively evaluated 110 AML patients treated with HMA (78 AZA, 32 DEC) as first-line therapy ou...
Camerini, A. Banna, G. L. Cinieri, S. Pezzuto, A. Mencoboni, M. Rosetti, F. Figueiredo, A. Rizzo, P. Ricci, A. Langenhoven, L.
...
Published in
Clinical and Translational Oncology
PurposeMetronomic oral vinorelbine (MOV) could be a treatment option for unfit patients with advanced non-small cell lung cancer (NSCLC) based on its safety profile and high patient compliance.MethodsWe retrospectively collected data on 270 patients [median age 76 (range 48–92) years, M/F 204/66, PS 0 (27)/1 (110)/≥ 2 (133), median of 3 serious com...
Pasini, Felice Barile, Carmen Caruso, Donatella Modena, Yasmina Fraccon, Anna Paola Bertolaso, Laura Menon, Daniela La Russa, Francesca Crepaldi, Giorgio Bononi, Antonio
...
Published in
Investigational New Drugs
Background Oral metronomic therapy (OMV) is particularly suitable for palliative care, and schedules adapted for unfit patients are advisable. This study investigated the effects of oral vinorelbine given every other day without interruption and its pharmacokinetic profile in patients with advanced lung cancer. Materials and Methods Ninety-two pati...
Merli, Francesco Mammi, Caterina Ilariucci, Fiorella
Published in
Current Oncology Reports
Although the achievement of deep and long lasting remissions is a realistic goal of therapy in the fit patient with chronic lymphocytic leukemia (CLL), this disease typically affects elderly patients who also show one or more concomitant pathological conditions or functional limitations that have an additive effects on the reduction of patient’s li...
Tawfik, Bernard Sliesoraitis, Sarunas Lyerly, Susan Klepin, Heidi D. Lawrence, Julia Isom, Scott Ellis, Leslie R. Manuel, Megan Dralle, Sarah Berenzon, Dmitriy
...
Published in
Annals of Hematology
The hypomethylating agents (HAs), azacitidine and decitabine, have emerged as an alternative to initial and salvage therapy in patients with acute myeloid leukemia (AML). Little is known about how AML responds to hypomethylating agents after standard therapy, and the activity of these agents in a real-world setting is not well studied. We retrospec...
